FDA declines to approve J&J arthritis drug sirukumab
A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake/ (Reuters) - (The Sept. 22 story has been corrected to remove the reference to Humira being a Jak-inhibitor in the final paragraph. Humira is a TNF-inhibitor.) The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. The FDA's decision is in keeping with an advisory panel's ...
Click
To Read Full Article